Compare iShares Broad USD Investment Grade Corporate Bond (USIG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Broad USD Investment Grade Corporate Bond vs Zoetis Inc — how do they compare? iShares Broad USD Investment Grade Corporate Bond trades at $50.3, while Zoetis Inc trades at $72.92 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while iShares Broad USD Investment Grade Corporate Bond pays none. Which is the better fit depends on your goals.
| USIG | ZTS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $52.69 | $156.76 |
52-Week Low | $50.18 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USIG is trading at $50.32, up 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments, with the latest being $0.21 per share. A key development is AM Best's affirmation of credit ratings for USIG subsidiaries following a transaction with Tiptree Inc., as reported by Business Wire on July 30, 2026.
The outlook is cautious due to bearish technical indicators and limited fundamental data availability. Investment opportunities may arise from stable dividend payments and institutional interest, such as Bank of New York Mellon Corp increasing its stake. Risks include reliance on external financial data and market sentiment shifts.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
